Arbutus FDA Lifts IND Hold for AB-101 Oral PD-L1 Inhibitor

Arbutus Biopharma announced that the FDA has lifted the clinical hold on its Investigational New Drug application for AB-101, an oral PD-L1 inhibitor, allowing the company to further evaluate its potential for treating chronic HBV infection.